Overview

Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2030-05-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of sunvozertinib as neoadjuvant therapy in patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China